CorMedix Inc $CRMD Shares Acquired by Quantinno Capital Management LP

Quantinno Capital Management LP boosted its stake in CorMedix Inc (NASDAQ:CRMD) by 1,006.4% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 124,909 shares of the company’s stock after buying an additional 113,619 shares during the period. Quantinno Capital Management LP’s holdings in CorMedix were worth $848,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Russell Investments Group Ltd. raised its position in shares of CorMedix by 22.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 6,553 shares of the company’s stock worth $81,000 after buying an additional 1,190 shares in the last quarter. Gryphon Financial Partners LLC boosted its holdings in shares of CorMedix by 6.3% in the first quarter. Gryphon Financial Partners LLC now owns 27,401 shares of the company’s stock valued at $186,000 after acquiring an additional 1,618 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of CorMedix by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,987 shares of the company’s stock valued at $222,000 after acquiring an additional 1,631 shares in the last quarter. Financial Management Professionals Inc. acquired a new position in shares of CorMedix during the fourth quarter valued at approximately $25,000. Finally, Comerica Bank increased its stake in shares of CorMedix by 454.6% during the third quarter. Comerica Bank now owns 2,690 shares of the company’s stock valued at $31,000 after acquiring an additional 2,205 shares during the period. Institutional investors and hedge funds own 34.18% of the company’s stock.

Wall Street Analysts Forecast Growth

CRMD has been the subject of a number of research analyst reports. Royal Bank Of Canada upped their target price on CorMedix from $13.00 to $14.00 and gave the stock an “outperform” rating in a research report on Friday. Leerink Partners lifted their price target on CorMedix from $13.00 to $14.00 and gave the company an “outperform” rating in a research report on Tuesday, April 28th. Zacks Research upgraded CorMedix from a “strong sell” rating to a “hold” rating in a report on Friday, May 15th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of CorMedix in a report on Tuesday, August 11th. Finally, Citizens Jmp reiterated a “market outperform” rating and issued a $19.00 price target on shares of CorMedix in a research report on Tuesday, April 28th. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $15.00.

CorMedix Price Performance

Shares of NASDAQ:CRMD opened at $7.67 on Tuesday. The company has a market capitalization of $597.80 million, a PE ratio of 3.58 and a beta of 1.50. The company has a debt-to-equity ratio of 0.31, a quick ratio of 2.36 and a current ratio of 2.56. The stock has a fifty day moving average of $8.12 and a 200-day moving average of $7.64. CorMedix Inc has a one year low of $6.13 and a one year high of $14.96.

CorMedix (NASDAQ:CRMD) last announced its earnings results on Thursday, August 13th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $0.05. CorMedix had a return on equity of 40.52% and a net margin of 40.49%.The company had revenue of $101.93 million for the quarter, compared to analyst estimates of $96.04 million. As a group, equities analysts anticipate that CorMedix Inc will post 0.54 EPS for the current fiscal year.

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.